한빛사
>
한빛사논문
한빛사논문
- 조회125
Biomaterials, Available online 9 December 2024 | https://doi.org/10.1016/j.biomaterials.2024.123004
Redox-activatable inhalable mucoadhesive proteinic nanotherapeutics for targeted treatment of lung cancer
Yeonsu Jeong a, Yun Seop Shim b, Yun Kee Jo b,c, Hyung Joon Cha a,d
aDepartment of Chemical Engineering, Pohang University of Science and Technology, Pohang 37673, Republic of Korea
bDepartment of Biomedical Convergence Science and Technology, Advanced Institute of Science and Technology, Kyungpook National University, Daegu 41566, Republic of Korea
cCell and Matrix Research Institute, Kyungpook National University, Daegu 41944, Republic of Korea
dMedical Science and Engineering, School of Convergence Science and Technology, Pohang University of Science and Technology, Pohang 37673, Republic of Korea
Corresponding authors: Yun Kee Jo, Hyung Joon Cha
aDepartment of Chemical Engineering, Pohang University of Science and Technology, Pohang 37673, Republic of Korea
bDepartment of Biomedical Convergence Science and Technology, Advanced Institute of Science and Technology, Kyungpook National University, Daegu 41566, Republic of Korea
cCell and Matrix Research Institute, Kyungpook National University, Daegu 41944, Republic of Korea
dMedical Science and Engineering, School of Convergence Science and Technology, Pohang University of Science and Technology, Pohang 37673, Republic of Korea
Corresponding authors: Yun Kee Jo, Hyung Joon Cha
Abstract
Inhalation delivery has been considered a promising choice for treating lung cancer because it can shuttle therapeutic payloads directly to cancer tissues via simple and noninvasive procedures while reducing systemic toxicity. However, its clinical application still faces challenges, especially for delivering hydrophobic chemotherapeutic drugs, due to poor absorption on mucosal tissues and limited therapeutic performance. Herein, we propose inhalable mucoadhesive proteinic nanoparticles (NPs) capable of facilitating reliable pulmonary drug delivery and redox-responsive anticancer therapeutic effects to realize noninvasive, localized treatment of lung cancer in a highly biocompatible, site-specific manner. Thiolated mussel adhesive protein (MAP)-based NPs (thMAP NPs) can be administered to target tissues via an easy and facile nebulization process due to their superior MAP-driven adhesion ability and sufficient structural integrity. Curcumin (Cur)-loaded thMAP NPs (thMAP@Cur NPs) demonstrated efficient cellular uptake through the thiol-mediated pathway and controlled the intracellular release of Cur in response to the reductive environment in cancer cells. The nebulized thMAP@Cur NPs elicited prolonged retention in lung tissue without causing any detectable adverse effects, leading to significant inhibition of metastatic lung cancer in vivo. Thus, these protein-based redox-responsive mucoadhesive NPs hold great promise as robust inhalable drug delivery platforms to achieve effective, localized treatment of pulmonary cancer and other respiratory diseases.
논문정보
- Research article
- 2024년 12월 (BRIC 등록일 2024-12-11)
- 국내 연구진
- 바이오·의료융합 > 바이오소재
관련 보도자료
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
관련분야 논문보기
해당논문 저자보기
